Radiomer Therapeutics has launched under Fannin Partners with an undisclosed amount of seed funding. Photo via Getty Images

Fannin Partners has done it again. The Houston-based life science development group behind medtech companies Procyrion and Allterum Therapeutics announced yesterday that it has launched Radiomer Therapeutics. With an undisclosed amount of pre-seed funding, Radiomer joins the $242 million-strong Fannin portfolio.

Radiomer uses Fannin’s proprietary Raptamer platform to target vectors and ligands for theranostic application. The cancer-fighting technology is a targeting agent that can address serious maladies including breast, lung, colorectal, prostate, and head and neck cancers.

And with Radiomer’s launch, Fannin is moving with its trademark aggressiveness. Lead programs expected to complete Phase 0 imaging/dosimetry trial(s) in cancer patients in the first quarter of next year. Those will be closely followed by therapeutic programs.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, says in a press release. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

Varadhachary has operated Radiomer in stealth mode since its 2023 inception. However, Raptamer has been in the company’s portfolio since 2019. The new company has been using the platform to generate data with the rights to radiopharmaceutical applications for the past year.

“Our lead programs include Radiomers targeting both well-established and first-in-class cancer targets,” adds Dr. Phil Breitfeld, Radiomer’s chief medical officer. “Our imaging/dosimetry trials are designed to provide clinical evidence of tumor targeting and biodistribution information, positioning us to rapidly initiate a therapeutic program(s) if successful.”

For over a decade, Fannin has developed and supported promising life science innovations by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary said on the Houston Innovators Podcast earlier this year.

Procyrion has announced the closing of its series E round of funding. Photo via Getty Images

Houston medical device company secures $57.7M to fund journey to FDA approval, commercialization

fresh funding

Houston-born and bred medical device company, Procyrion, has completed its series E with a raise of $57.7 million, including the conversion of $10 million of interim financing.

Procyrion is the company behind Aortix, a pump designed to be placed in the descending thoracic aorta of heart failure patients, which has been shown to improve cardiac performance in seriously ill subjects. The money raised will allow the company to proceed with a the DRAIN-HF Study, a pivotal trial that will be used for eventual FDA approval and commercialization.

The Aortix is the brainchild of Houston cardiologist Reynolds Delgado. According to Procyrion’s CSO, Jace Heuring, Delgado, gained some of his experience with devices for the heart working with legendary Texas Heart Institute surgeon O.H. “Bud” Frazier. He filed his first patents related to the Aortix in 2005.

Heuring says that the first prototypes were built in 2011, followed by the final design in 2018. CEO Eric Fain, a California-based MD and with more than 30 years in the medical device industry, joined the company in 2018 ahead of the final design, primed to bring Aortix to the public. He visits the company’s Houston headquarters, across the street from Central Market, on a regular basis.

The device’s pilot study of 18 patients was completed in 2022. Those encouraging results paved the way for the current study, which will include an enrollment of 134 patients. The randomized study will seek to treat patients with acute decompensated heart failure. Half will be treated with standard-of-care therapy, the other half will be catheterized with an Aortix pump. A separate arm of the study will seek to treat end-stage heart failure patients who would otherwise be deemed too sick for either a transplant or an LVAD permanent pump. Fort-five healthcare centers in the United States will participate, including Texas Heart Institute.

“One of the key characteristics is [the patients] are retaining a lot of fluid,” explains Heuring in a video interview. “And when I say a lot, I mean it could be 25 or 30 or 40 pounds of fluid or more. When we put our pump in, one of the main goals is to reduce that fluid load.”

On average, about 11 liters of fluid came off of each patient. Many of those end-stage patients had previously been considered for both a heart and kidney transplant, but after using the Aortix, their kidneys responded so well that they were able to get only the heart transplant.

“These patients really are in dire straits and come into the hospital and today the only proven therapy to help these patients is to administer high doses of intravenous diuretic and some other cardiac drugs and in about 25 percent of patients those therapies are ineffective,” says Fain.

If Aortix gains approval, these sickest of the sick, usually consigned to hospice care, will have hope.

Thanks to the Series E, led by Houston’s Fannin Partners, returning investors, including Bluebird Ventures, the Aortix is inching closer to commercialization. Besides funding the DRAIN-HR study, Procyrion will also use the funds for internal programs to improve product manufacturability. One more step towards meaning advanced heart failure may not always be a death sentence.

Last month, Atul Varadhachary, managing director of Fannin, joined the Houston Innovators Podcast and alluded to Procyrion's raise. The company was born out of Fannin and still resides in the same building as Fannin.

Aortix is a pump designed to be placed in the descending thoracic aorta of heart failure patients. Photo via Procyrion

Atul Varadhachary of Fannin joins the Houston Innovators Podcast. Photo via LinkedIn

Houston innovator plays the long game of life science innovation with optimized capital efficiency

HOUSTON INNOVATORS PODCAST EPISODE 222

Commercializing a life science innovation that has the potential to enhance or even save the lives of millions of patients is a marathon, not a sprint. That's how Atul Varadhachary thinks of it, and he's leading an organization that's actively running that race for several different early-stage innovations.

For over a decade, Fannin has worked diligently to develop promising life science innovations — that start as just an idea or research subject — by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The model is different from what you'd see at an accelerator or incubator, and it also varies from the path taken by an academic or research institution.

The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary, managing director at Fannin, says on the Houston Innovators Podcast.



Fannin addresses what Varadhachary calls a twin bottleneck in Houston's life science innovation ecosystem. Not only does Houston not attract the funding biotech startups need desperately to grow their companies, but hiring is a major issue as the city isn't home to an established labor pool of experienced product developers within the industry.

"The challenge is that product development is more complex — it requires innovation, but that's not sufficient. When you ask people why we lag in the product development in the life sciences — although we are home to the largest medical center in the country, we don't even make list of top 10 biotech clusters — the usual answer is that we don't have enough biotech investors," Varadhachary says.

"But that puts the cart before the horse," he continues. "Investors invest in people not just ideas. Although we have an amazing pool of researchers and clinicians, we lack experienced product developers."

In more ways than one, Fannin is addressing this problem. For all of its several ongoing programs, Fannin acts as the leadership team for the technologies. Its core employees — there are about 20 currently — work on all of the companies, which are developing a range life science innovations, from Brevitest, a point-of-use immunoassay platform, to Procyrion, an intra-aortic pump for congestive heart failure patients.

Fannin's programs also range in stage, which Varadhachary outlines on the show to be three different phases. The earliest stage programs will have Fannin's team working directly on early testing, product development, and grant writing, while the later stage programs will have built out a dedicated team and raise venture investment.

Another way Fannin is addressing Houston's lack of life science product developers is through its Fannin Talent Development Program, which has given around 350 individuals an opportunity to gain critical product development experience.

With 10 years under its belt, Fannin — as well as the greater Houston life science innovation ecosystem — is at a point where it can soon produce exits needed to firm up Houston as a life science leader.

"Clearly, we've got the base elements required to be a successful ecosystem, and they continue to grow," Varadhachary says of Houston. "Typically you need one or two really big success stories — especially if those success stories result in a company being sold, leaving behind experienced product developers with money in their pockets — that's often what will supercharge the next cycle of development. I'm hoping that will happen in Houston in the next five years, decade, or so."

Houston-based Procyrion has closed a $30 million round — doubling its total funding to date. Getty Images

Houston medical device company closes $30 million round

Follow the money

A clinical-stage medical device company based in Houston has rounded up $30 million for its Series D funding. Procyrion Inc.'s round was lead by Bluebird Ventures — a new funding partner for the company.

Procyrion is developing a blood pump, called the Aortix™ system, that's optimized for patients with heart and kidney failure. Joining in on the round with Bluebird are return investors, including Fannin Partners, Scientific Health Development, the State of Texas, and an undisclosed strategic investor. This round has now more than doubled the company's total funding, bringing that figure now to $59 million.

"Of the more than 1 million patients per year in the U.S. admitted to the hospital with acute decompensated heart failure, 25 to 30 percent also have worsening renal function," says Eric S. Fain, president and CEO of the company, in a release. "These are typically the most difficult to treat patients with high mortality and rehospitalization rates."

The funds, Fain says, will go toward advancing the medical device, specifically enhancing the system's ability to decongest cardio renal patients in the company's pilot program.

"Today there is a major gap in effective therapies that are available to treat these critically ill patients, and as such, there is a significant opportunity to improve patient outcomes," Fain continues in the release. "The Aortix device is uniquely designed and positioned in the body to simultaneously decrease the workload of the heart and improve kidney function."

The Aortix device is a solution for patients who haven't seen success from medical therapy, but don't have the immediate need for a transplant or more drastic solution. The device is thinner than a pencil, the release says, and can be inserted in a matter of minutes in a cath-lab setting. The size and ease of application could be transformational for the large population of heart patients that would need it.

In addition to the funds, Jeff Bird, managing director of Bluebird Ventures, will join the company's board of directors.

"The Procyrion Aortix device provides an elegant solution for managing heart failure, a serious and difficult-to-treat problem," says Bird in the release. "We are excited to work with this experienced team as they begin clinical testing."


The device is thinner than a pencil and can be inserted in less than 10 minutes. Photo via procyrion.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hailed as one of America's 10 best cities for startups

Startup Report

Houston's favorable economic climate is enticing new opportunities for entrepreneurship and growth, and now the city is being hailed as the 7th-best U.S. city for starting a business.

The recognition comes in CommercialCafe's recent "Best Cities for Startups" report, published December 10. The study analyzed large U.S. cities across two population categories – cities with more than 1 million residents and cities with populations between 500,000 and 1 million residents. The report analyzed relevant metrics such as office or coworking costs, Kickstarter funding success, startup density, and survival rates, among others.

Across the biggest U.S. cities with over a million residents, Phoenix, Arizona landed on top as the No. 1 best place to start a new business.

The report's findings revealed 10.6 percent of all businesses in Houston are startups that have been active for less than a year. These new businesses have a survival rate of 64.5 percent, meaning just under two-thirds of all startups in the city will still be running up to five years after they were first established.

Over the last five years, the number of new businesses established in Houston has grown nearly 15 percent. CommercialCafe said new businesses in cities with high startup growth rates tend to "attract top talent" which can eventually lead to securing "vital funding for expansion."

Independent professionals – also known as freelancers – are another crucial resource for new businesses that may need "specialized services" for a fixed amount of time, the report said. Houston's freelance workforce has grown about 9 percent from 2019-2023, and the analysis found there were 97,295 freelancers working in Houston in 2023, compared to 89,528 in 2019.

"Generally, cities in the South and Southwest have experienced strong growth during the surveyed period, in contrast to California cities like Los Angeles and San Diego, where the share of freelancers and gig workers has either stagnated or slightly declined," the report said.

Houston boasts the second-cheapest office space rent nationally, the report found. The average asking price for a 1,000-square-foot workspace (for five employees) in the city added up to $27,124 annually. For startups that want greater flexibility for their workers, the annual cost for a coworking space for the same number of employees in Houston came out to $13,200, which is the fourth-most affordable rate in the U.S.

Other Texas cities with attractive economic environments for startups

Texas, as a whole, is one of the strongest states for starting a new business. Other than Houston, San Antonio (No. 2), Dallas (No. 3), and Fort Worth (No. 4) were also recognized among the top 10 best places to start a business in the category of U.S. cities with more than a million residents.

Austin topped a separate ranking of best cities to start a business with 500,000 to 1 million residents.

"Specifically, the Texas capital was the frontrunner for indicators that looked at the overall share of startups within the local economy, as well as growth rates in five years (2019 to 2023)," the report said. "On top of that, Austin also topped the rankings for its percentage of college-educated residents and its consulting firms, which provide vital support for burgeoning enterprises."

The top 10 best cities to start a new business are:

  • No. 1 – Phoenix, Arizona
  • No. 2 – San Antonio, Texas
  • No. 3 – Dallas, Texas
  • No. 4 – Fort Worth, Texas
  • No. 5 – Jacksonville, Florida
  • No. 6 – San Diego, California
  • No. 7 – Houston, Texas
  • No. 8 – Philadelphia, Pennsylvania
  • No. 9 – Chicago, Illinois
  • No. 10 – Los Angeles, California
---

This article originally appeared on CultureMap.com.

Top Houston space news of 2025 soars with NASA deals, lunar missions

Year in Review

Editor's note: As 2025 comes to a close, we're looking back at the stories that defined Houston innovation this year. The space tech sector soared with companies landing huge NASA contracts and furthering their lunar missions. Here are the 10 biggest Houston space tech stories of the year:

Houston native picked for 2025 class of NASA astronaut candidates

Houston native Anna Menon, posing below the first A in “NASA,” is one of 10 new NASA astronaut candidates. Photo courtesy NASA.

NASA has selected 10 new astronaut candidates, including one whose hometown is Houston, for its 2025 training class. The candidates will undergo nearly two years of training before they can assume flight assignments.

Intuitive Machines lands $9.8M to complete orbital transfer vehicle

Intuitive Machines expects to begin manufacturing and flight integration on its orbital transfer vehicle as soon as 2026. Photo courtesy Intuitive Machines.

Houston-based Intuitive Machines, which rang the NASDAQ opening bell July 31, secured a $9.8 million Phase Two government contract for its orbital transfer vehicle. The contract will push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin.

Houston tech company tapped by NASA for near space initiative

Intuitive Machines is among four companies awarded contracts for NASA’s Near Space Network. Photo via intuitivemachines.com

In January, Intuitive Machines nailed down a NASA deal to expand the agency’s communications network for spacecraft. Additionally, NASA completed the first round of “human in the loop” testing for Intuitive Machines’ Moon RACER lunar terrain vehicle at the agency’s Johnson Space Center. RACER (Reusable Autonomous Crewed Exploration Rover) is one of three commercially developed unpressurized lunar terrain vehicles being considered for NASA’s Artemis lunar initiative.

Texas Space Commission doles out $5.8 million to Houston companies

Axiom Space and FluxWorks are the latest Houston-area companies to receive funding from the Texas Space Commission. Photo via Getty Images.

Two Houston-area companies landed more than $5.8 million in funding from the Texas Space Commission. The commission granted up to $5.5 million to Houston-based Axiom Space and up to $347,196 to Conroe-based FluxWorks in June 2025. The two-year-old commission previously awarded $95.3 million to 14 projects. A little over $34 million remains in the commission-managed Space Exploration and Aeronautics Research Fund.

Houston company awarded $2.5B NASA contract to support astronaut health and space missions

NASA has awarded KBR a five-year, $2.5 billion Human Health and Performance Contract. Photo courtesy NASA.

Houston-based technology and energy solution company KBR was awarded a $2.5 billion NASA contract to support astronaut health and reduce risks during spaceflight missions. Under the terms of the Human Health and Performance Contract 2, KBR will provide support services for several programs, including the Human Research Program, International Space Station Program, Commercial Crew Program, Artemis campaign and others. This will include ensuring crew health, safety, and performance; occupational health services and risk mitigation research for future flights.

Houston engineering firm lands $400M NASA contract

Bastion Technologies has been tapped to provide safety and mission services for NASA's Marshall Space Flight Center in Alabama. Photo via nasa.gov.

NASA granted Houston-based Bastion Technologies Inc. the Safety and Mission Assurance II (SMAS II) award with a maximum potential value of $400 million. The award stipulates that the engineering and technical services company provide safety and mission services for the agency’s Marshall Space Flight Center in Huntsville, Alabama.

Houston startups win NASA funding for space tech projects

Houston startups were recently named among the nearly 300 recipients that received a portion of $44.85 million from NASA to develop space technology. Photo via NASA/Ben Smegelsky

Three Houston startups were granted awards from NASA in July 2025 to develop new technologies for the space agency. The companies were among nearly 300 recipients that received a total agency investment of $44.85 million through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I grant programs.

Texas Republicans are pushing to move NASA headquarters to Houston

Here's why Texas Republicans think NASA's headquarters should move to Texas in 2028. File photo.

Two federal lawmakers from Texas spearheaded a campaign to relocate NASA’s headquarters from Washington, D.C., to the Johnson Space Center in Houston’s Clear Lake area. Houston faces competition on this front, though, as lawmakers from two other states are also vying for this NASA prize. With NASA’s headquarters lease in D.C. set to end in 2028, U.S. Sen. Ted Cruz, a Texas Republican, and U.S. Rep. Brian Babin, a Republican whose congressional district includes the Johnson Space Center, wrote a letter to President Trump touting the Houston area as a prime location for NASA’s headquarters.

Intuitive Machines to acquire NASA-certified deep space navigation company

Intuitive Machines will acquire Kinetx, which marks its entry into the precision navigation and flight dynamics segment of deep space operations. Photo via Getty Images.

In August 2025, Intuitive Machines agreed to buy Tempe, Arizona-based aerospace company KinetX for an undisclosed amount. The deal is expected to close by the end of this year. KinetX specializes in deep space navigation, systems engineering, ground software and constellation mission design. It’s the only company certified by NASA for deep space navigation. KinetX’s navigation software has supported both of Intuitive Machines’ lunar missions.

Axiom Space launches semiconductor and astronaut training initiatives

Axiom Space chief astronaut Michael López-Alegría (left) trains with Axiom’s new “Project Astronaut,” Emiliano Ventura. Photo courtesy of Axiom Space.

In fall 2025, Axiom Space, a Houston-based commercial spaceflight and space infrastructure company, launched initiatives in two very different spheres — semiconductors and astronaut training.

Paraplegic engineer becomes first wheelchair user to blast into space

Space News

A paraplegic engineer from Germany blasted off on a dream-come-true rocket ride with five other passengers Saturday, December 20, leaving her wheelchair behind to float in space while beholding Earth from on high.

Severely injured in a mountain bike accident seven years ago, Michaela Benthaus became the first wheelchair user in space, launching from West Texas with Jeff Bezos’ company Blue Origin. She was accompanied by a retired SpaceX executive also born in Germany, Hans Koenigsmann, who helped organize and, along with Blue Origin, sponsored her trip. Their ticket prices were not divulged.

An ecstatic Benthaus said she laughed all the way up — the capsule soared more than 65 miles (105 kilometers) — and tried to turn upside down once in space.

“It was the coolest experience,” she said shortly after landing.

The 10-minute space-skimming flight required only minor adjustments to accommodate Benthaus, according to the company. That’s because the autonomous New Shepard capsule was designed with accessibility in mind, “making it more accessible to a wider range of people than traditional spaceflight,” said Blue Origin’s Jake Mills, an engineer who trained the crew and assisted them on launch day.

Among Blue Origin’s previous space tourists: those with limited mobility and impaired sight or hearing, and a pair of 90-year-olds.

For Benthaus, Blue Origin added a patient transfer board so she could scoot between the capsule’s hatch and her seat. The recovery team also unrolled a carpet on the desert floor following touchdown, providing immediate access to her wheelchair, which she left behind at liftoff. She practiced in advance, with Koenigsmann taking part with the design and testing. An elevator was already in place at the launch pad to ascend the seven stories to the capsule perched atop the rocket.

Benthaus, 33, part of the European Space Agency’s graduate trainee program in the Netherlands, experienced snippets of weightlessness during a parabolic airplane flight out of Houston in 2022. Less than two years later, she took part in a two-week simulated space mission in Poland.

“I never really thought that going on a spaceflight would be a real option for me because even as like a super healthy person, it’s like so competitive, right?” she told The Associated Press ahead of the flight.

Her accident dashed whatever hope she had. “There is like no history of people with disabilities flying to space," she said.

When Koenigsmann approached her last year about the possibility of flying on Blue Origin and experiencing more than three minutes of weightlessness on a space hop, Benthaus thought there might be a misunderstanding. But there wasn't, and she immediately signed on.

It’s a private mission for Benthaus with no involvement by ESA, which this year cleared reserve astronaut John McFall, an amputee, for a future flight to the International Space Station. The former British Paralympian lost his right leg in a motorcycle accident when he was a teenager.

An injured spinal cord means Benthaus can’t walk at all, unlike McFall who uses a prosthetic leg and could evacuate a space capsule in an emergency at touchdown by himself. Koenigsmann was designated before flight as her emergency helper; he and Mills lifted her out of the capsule and down the short flight of steps at flight’s end.

“You should never give up on your dreams, right?” Benthaus urged following touchdown.

Benthaus was adamant about doing as much as she could by herself. Her goal is to make not only space accessible to the disabled, but to improve accessibility on Earth too.

While getting lots of positive feedback within “my space bubble,” she said outsiders aren't always as inclusive.

“I really hope it’s opening up for people like me, like I hope I’m only the start," she said.

Besides Koenigsmann, Benthaus shared the ride with business executives and investors, and a computer scientist. They raised Blue Origin’s list of space travelers to 86.

Bezos, the billionaire founder of Amazon, created Blue Origin in 2000 and launched on its first passenger spaceflight in 2021. The company has since delivered spacecraft to orbit from Cape Canaveral, Florida, using the bigger and more powerful New Glenn rocket, and is working to send landers to the moon.